MV-CEA
AXP000112.1 · Oncolytic virus
- Platform
- measles virus (Edmonston-NSe vaccine lineage)
- Originator
- Mayo Clinic
- Sponsor
- Mayo Clinic
Names
| Name | Type | Source |
|---|---|---|
| MV-CEA | preferred name, code | curator, ncit |
| Carcinoembryonic Antigen-Expressing Measles Virus | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Paramyxoviridae
- Virus
- measles morbillivirus (NCBI Taxonomy 11234)
- Strain
- Edmonston-NSe vaccine lineage
- Replication
- replicating
- Modifications
- CEA (soluble human carcinoembryonic antigen) cassette inserted as a marker gene
- Transgenes
- CEACAM5
- Route
- intraperitoneal
- Source
- evidence
Cross-references
- NCI Thesaurus
- C64775
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT00390299 | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | Completed | Phase 1 | 2006-10-23 | 2018-11-29 | 23 | Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Mixed Glioma; Recurrent Glioblastoma |
| NCT00408590 | Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Completed | Phase 1 | 2004-04-19 | 2012-08 | 37 | Ovarian Cancer; Primary Peritoneal Cavity Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38216554 | Carcinoembryonic antigen-expressing oncolytic measles virus derivative in recurrent glioblastoma: a phase 1 trial. | Nature communications | 2024 | cited by trial NCT00390299 |
| PMID 20103634 | Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. | Cancer research | 2010 | name in abstract: MV-CEA |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41228258 | The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management. | Cancers | 2025 | name in abstract: MV-CEA |
| PMID 34004331 | Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme. | Seminars in cancer biology | 2022 | name in abstract: MV-CEA |
| PMID 36555262 | Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses. | International journal of molecular sciences | 2022 | name in abstract: MV-CEA |
| PMID 28228086 | Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. | Current cancer drug targets | 2018 | name in abstract: MV-CEA |
| PMID 22914495 | Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. | Gene therapy | 2013 | name in abstract: MV-CEA |
| PMID 22796607 | Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human neuroblastoma through a CD46 and nectin 4-independent pathway. | Cancer letters | 2012 | name in abstract: Carcinoembryonic Antigen-Expressing Measles Virus |
| PMID 23009685 | Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human hepatoblastoma. | BMC cancer | 2012 | name in abstract: MV-CEA |
| PMID 18973133 | Engineered measles virus as a novel oncolytic therapy against prostate cancer. | The Prostate | 2009 | name in abstract: MV-CEA |
| PMID 19169959 | Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. | Current opinion in molecular therapeutics | 2009 | name in abstract: MV-CEA |
| PMID 18356818 | Heat shock protein inhibitors increase the efficacy of measles virotherapy. | Gene therapy | 2008 | name in abstract: MV-CEA |
| PMID 18576918 | Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. | Human gene therapy | 2008 | name in abstract: MV-CEA |
| PMID 18056196 | Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2007 | name in abstract: MV-CEA |
| PMID 16543921 | Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. | Cancer gene therapy | 2006 | name in abstract: MV-CEA |
| PMID 16551872 | Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2006 | name in abstract: MV-CEA |
| PMID 16642271 | A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. | Breast cancer research and treatment | 2006 | name in abstract: MV-CEA |
| PMID 15746945 | Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. | Cancer gene therapy | 2005 | name in abstract: MV-CEA |
| PMID 12750267 | Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. | Cancer research | 2003 | name in abstract: MV-CEA |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01CA200507 | Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2017–2020 | name in abstract: MV-CEA |
| P50CA108961 | Optimizing Measles Virotherapy in the Treatment of Gliomas | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2004–2015 | name in title: MV-CEA |
| R01CA154348 | Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomas | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2011–2014 | name in abstract: MV-CEA |
| P50CA136393 | Optimizing Measles Virotherapy in the Treatment of Recurrent Ovarian Cancer | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2009–2013 | name in abstract: MV-CEA |
| R01CA136547 | Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2009–2012 | name in abstract: MV-CEA |
| R21CA123839 | Measles Virotherapy for Glioblastoma Multiforme | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2006–2007 | name in abstract: MV-CEA |
| R21CA103276 | Measles Virus Therapy for Ovarian Cancer | MAYO CLINIC ROCHESTER | GALANIS, EVANTHIA | 2003–2004 | name in abstract: MV-CEA |
Notes
Attenuated Edmonston-lineage measles virus engineered to express soluble CEA as a marker of viral gene expression. Dosed intraperitoneally in recurrent ovarian cancer (NCT00408590) and intratumorally/intracavitary in glioma; only the ovarian route is verified here.
How to cite
MV-CEA (AXP000112.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000112.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.